Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13191824 | 0.89 | ANPEP (0.35) | ANPEPENPEP | |
| SCHEMBL12128370 | 0.87 | ANPEP (0.34) | ANPEPENPEP | |
| SCHEMBL13754602 | 0.85 | SPHK1 (0.35) | ANPEPENPEP | |
| SCHEMBL804904 | 0.83 | ANPEP (0.40) | ANPEPENPEPRNPEP | |
| SCHEMBL16215356 | 0.82 | ANPEP (0.36) | ANPEPENPEPRNPEP | |
| SCHEMBL12928341 | 0.81 | ANPEP (0.35) | ANPEPENPEP | |
| SCHEMBL10049243 | 0.79 | ANPEP (0.40) | ANPEPENPEPRNPEP | |
| SCHEMBL12112882 | 0.79 | ANPEP (0.40) | ANPEPENPEPRNPEP | |
| SCHEMBL15507424 | 0.78 | ANPEP (0.39) | ANPEPENPEPRNPEP | |
| SCHEMBL13578970 | 0.78 | ANPEP (0.39) | ANPEPENPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017123860-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20170174763-A1 | NOGO Receptor-Mediated Blockade of Axonal Growth | YALE UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| US-20170014416-A1 | Compositions And Methods For Treatment Of Psychiatric Disorders | DUNN ROBERT T (US) | 2017-01-19 | — | — | US | disclosed |
| US-9539553-B2 | Corona-core microgel emulsifying agent and oil-in-water emulsified composition | SHISEIDO COMPANY, LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9290765-B2 | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (ARG) | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2016-03-22 | — | — | US | disclosed |
| US-20160078190-A1 | REPORTING MODULES | DEXCOM, INC. | 2016-03-17 | — | — | US | disclosed |
| US-9274132-B2 | Assay cartridge with reaction well | BECKMAN COULTER, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| US-9073975-B2 | Cyclic peptides, their preparation and their use as inhibitors of the platelet adhesion | SANOFI (FR) | 2015-07-07 | — | — | US | disclosed |
| US-20150044317-A1 | Topical Compositions for Reducing Visible Signs of Aging and Methods of Use Thereof | GANEDEN BIOTECH, INC. | 2015-02-12 | — | — | US | disclosed |
| US-7838250-B1 | Mixture comprising cardiac muscle protein specific immunoglobulin for use diagnosing/prognosing cardiovascular disorders | SINGULEX, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7809060-B2 | Moving picture stream generation apparatus, moving picture coding apparatus, moving picture multiplexing apparatus and moving picture decoding apparatus | PANASONIC CORPORATION (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-15 | — | — | US | disclosed |
| US-20090319212-A1 | MAGNETIC CRASH SENSOR | TK HOLDINGS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20080261242-A1 | Mixture comprising cardiac muscle protein specific immunoglobulin for use diagnosing/prognosing cardiovascular disorders | SINGULEX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007093012-A1 | CONOTOXIN ANALOGUES, AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE CONTAINING PEPTIDES | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| US-7244621-B2 | Method for interpreting tandem mass spectrometry data for clinical diagnosis of genetic disorders such as hypermethionemia | PEDIATRIX SCREENING, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7238531-B2 | Method for interpreting tandem mass spectrometry data for clinical diagnosis | PEDIATRIX SCREENING, INC. (US) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | ANPEP 481/4885ENPEP 296/4885RNPEP 279/4885 |
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | ITGA2B, ITGA2, ITGB2 | ANPEP 581/4885ENPEP 1421/4885RNPEP 442/4885 |
| US-20170014416-A1 | Compositions And Methods For Treatment Of Psychiatric Disorders | BHMT, SLC6A12, BHMT2 | ANPEP 3603/4885ENPEP 1388/4885RNPEP 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.